Tech Nation Exceptional Promise Founder Rejection: Appeal or Strengthen My Reapplication?

Stage 1
1

WhatsApp Image 2026-07-29 at 9.59.14 PM
WhatsApp Image 2026-07-29 at 9.59.14 PM1290Ă—1378 262 KB

Tech Nation Exceptional Promise Rejection: Appeal or Strengthen My Reapplication?

I recently received a rejection for my Tech Nation Global Talent application under the Exceptional Promise pathway

The panel confirmed that I was eligible for Exceptional Promise and that my recommendation letters were adequate. However, the Mandatory Criterion, OC1 and OC4 were not awarded.

Mandatory Criterion

My evidence included:

  • Winner of the Best AI Feature award at a competitive UK hackathon involving more than 96 teams.
  • Invited talk in a webinar on AI in healthcare.
  • Digital technology and AI workshop delivered at a leading university to an audience of more than 100 people.
  • Jury panel role for a startup innovation challenge.
  • External recognition award and media coverage.
  • Strategic collaboration MoU.
  • Leadership in developing and launching Product X.
  • Engagement through the NHS Innovation Service, including meetings with NIHR and Health Innovation Network South London regarding clinical validation, NHS adoption, real-world evidence and deployment.

The panel accepted that some activities were eligible but considered them too early-stage, with insufficient scale and wider-sector recognition.

OC1 – Innovation

I submitted Product X, a live AI-powered preventive healthcare application developed and deployed under Company A.

My evidence included:

  • End-to-end technical and product ownership.
  • Deployment on both the App Store and Play Store.
  • More than 700 early users, with users increasing daily.
  • Subscription revenue of over ÂŁ600 in the first two months.
  • Public frontend and backend repositories demonstrating technical ownership and open-source contribution.
  • A market survey of over 100 respondents showing strong demand and willingness to pay for subscription.
  • NHS Innovation Service engagement.
  • An innovation-collaboration meeting with the NIHR-funded D4D programme, which reviewed the product and showed interest in its potential adoption within the UK healthcare environment.
  • Independent market and investment interest from a technology company director who recognised the product’s scalability and commercial potential.
  • Reference letter from tech leader.

The panel recognised Product X as a genuine live product but considered the adoption, revenue and measurable impact too limited.

OC4 – Research Contribution

I submitted three first-authored, peer-reviewed AI healthcare papers, published and presented at IEEE and ACM conferences.

My supporting evidence included:

  • Research covering all three papers.
  • Public code repositories and open-source research implementations.
  • Translation of the research into features within the live Product X platform.
  • Independent academic recommendations and feedback.
  • Further research collaboration discussions with lecturers and PhD researchers.
  • Evidence that another researcher requested access to my implementation to build upon the work.
  • Continued academic engagement and knowledge sharing.

The panel accepted that first authorship was a genuine contribution but stated that the publications were recent and had limited adoption, reach and GitHub engagement.

Question:

I understand that the panel does not have to comment on every item. For a future reapplication, which improvements would have the greatest impact across MC, OC1 and OC4, for example stronger recognition from established technology organisations, greater user and revenue growth, formal UK healthcare pilots or partnerships, more research citations and independent adoption, and stronger GitHub engagement? Based on my current evidence, would you recommend requesting an endorsement review now or strengthening these areas and reapplying later?

The feedback did not specifically address several submitted items, including the NIHR-funded D4D meeting, HIN South London engagement, ongoing revenue, market and investment interest, open-source contribution, and independent interest in using my research.

I would be grateful for advice from anyone who has successfully appealed or reapplied after similar feedback.
@Raphael @Akash_Joshi @Francisca_Chiedu @Noddy

2

not sure tech nation takes exceptional promise again based on the recent evidence I have seen, because what is stated here contradicts their guidelines about potential for exceptional promise they should update their guidelines and let everyone know.

2 Likes
3

Review isn’t the right path here. The Official Guide is explicit that a Review is only for identifying processing mistakes, not for arguing against a substantive decision, and no new evidence can be submitted. The panel accepted your route, your recommenders, and the authenticity of your product and papers, so there’s no procedural error to raise. Focus on the reapplication.

Every MC item you submitted is an activity you organised, participated in, or won at an early-stage venue. The Guide’s MC examples lean on external recognition that exists independently of you, like published material in major trade publications about your work or a significant expert assessor role on a recognised panel. Replace the hackathon and workshop-style items with pieces where a well-established third party has recognised you at sector scale.

The innovation criterion measures commercial impact, and the Guide requires income beyond the founder’s salary along with traction that a formal set of accounts can substantiate. Your current numbers won’t clear that bar for a healthcare product. The strongest lift is converting one of the NHS conversations into a documented paid pilot with a Trust or partner, then evidencing it through a signed contract or filed accounts.

Recent papers get discounted because the Guide flags evidence made solely to support the timing of your application as unacceptable. Time is the main lever for the academic criterion. Delay the reapplication until at least one paper has an independent citation trail and the GitHub implementation shows external contributions.

2 Likes
4

Hi @Shahzain, So sorry about the feedback. On your question:

I understand that the panel does not have to comment on every item. For a future reapplication, which improvements would have the greatest impact across MC, OC1 and OC4

While rejection feedback can give some clues for further direction, I would advise that you don’t use it as a complete reference. Pick up each piece of evidence you are submitting for a new application and work on aligning them properly with the Tech Nation guidance. One mistake you should correct is submitting only evidence examples, as they also noted: “A number of these are eligible examples…” I don’t know how an award can be considered at a junior stage, considering you applied via the promise pathway, but from what you’ve listed here, your evidence does not show that you were recognised. So you need to work on the recognition and impact elements. Also, make sure your evidence are sustained when necessary, that’s what I think was the context of the junior.

For OC1, you submitted some evidence examples without demonstrating what you did, which is the primary requirement.

You showed that you made sales from a platform, but you didn’t show the innovation. The first thing to demonstrate is the innovation, then validate that it was actually innovative through a patent, sales, user adoption, and partnerships.

All the best.

3 Likes
5

Really sorry to hear about the outcome — that’s a genuinely strong-looking evidence set on paper, and I can imagine how frustrating the feedback is given the effort behind it.

  1. For OC4 — did you include citation counts or Google Scholar data for the three papers as part of your evidence, or was “limited reach” more of an inference the panel made without you submitting citation metrics? If you did include citations, roughly how many did each paper have, and were they mostly independent researchers?

  2. For OC1 — did you show growth trend (e.g. week-over-week user/revenue numbers) or mainly a point-in-time snapshot? Wondering if trajectory matters as much as absolute numbers.

1 Like
6

hsong’s questions point at the right pressure points. Citation count on each of the three papers matters more than authorship for OC4. If the papers have zero independent citations at submission time, the panel’s read of limited reach becomes hard to argue against, and no reapplication improves it without waiting for citations to accumulate. Growth trend is what turns the OC1 numbers into evidence of momentum. Week-over-week user and revenue graphs alongside the 700-user and £600-revenue figures give the assessor a trajectory rather than a static snapshot.

The stronger structural fix is on MC. Every activity in the current pack sits at your own venue, either organised by you or on a platform you engaged with. The Guide’s MC examples turn on recognition that arrives unsolicited from sector-scale third parties. Focus the reapplication on two or three genuinely externally validating pieces you can build in six months, and drop the rest. A documented paid pilot with an NHS Trust, coverage in a national tech publication, or a speaking slot at a sector-recognised conference would each carry more than the current list combined.

Reapply rather than review. Six months is the right timeline if the pilots and citations both start moving in that window.

3 Likes
7

@tunde1234 Thanks for your comment . That’s what has confused me as well. If you have seen recent Exceptional Promise reapplications succeed, I’d really appreciate any advice on what made the difference or what I should strengthen in my reapplication.

8

@Akash_Joshi Thanks so much for your help and for explaining everything so clearly. I understand your points much better now.

For OC4, all of my papers were published in 2026, so they don’t have independent citations yet. I expect citations to start coming towards the end of this year. Given that, how can I best address the “too recent” concern? Would it help to add another publication?

9

Another 2026 paper doesn’t help. The Guide flags evidence created specifically to support the timing of an application, and a fresh publication added right before you reapply reads exactly that way. Adding a fourth paper compounds the too-recent problem.

The lever is independent uptake of the three you already have. An independent citation on each, or external contributors picking up the GitHub implementation, would shift the limited-reach verdict in a way another paper cannot. Six months is enough for at least some of that to accrue if the work is being read.

If citations start landing later this year as you expect, submit then. Reapplying earlier with the same zero-citation footprint on the existing papers won’t move OC4.

2 Likes
10

@Raphael Thank you so much for your detailed feedback. It has really helped me understand where my application fell short. For my reapplication, would you recommend strengthening my existing evidence with better proof of recognition, innovation, and impact, or replacing some of it with entirely new evidence?

1 Like
11

@hsong427

All of my papers were published in 2026, so they didn’t have any citations at the time of submission, although the research itself started around two years ago. I included my Google Scholar profile as part of the evidence. I also submitted evidence showing that an independent researcher contacted me by email to reproduce my paper’s code and build on my research for their own project, hoping this would demonstrate early academic impact.

For OC1, I mainly presented a point-in-time snapshot of users and revenue rather than a growth trajectory. Looking back, I think that may have been a weakness.

12

Hi @Shahzain, the assessment indicates that the evidence submitted was considered to be at an early stage, with limited scale, external validation, and measurable impact across the relevant criteria.

For the Mandatory Criterion, I would focus on gaining stronger third-party recognition from established organisations, industry awards, media coverage, speaking opportunities, or partnerships that demonstrate wider sector impact rather than early-stage activities.

For OC1, your product has been recognised as genuine, but the feedback clearly points to traction. Growing your user base, revenue, customer retention, NHS pilots, commercial partnerships, or enterprise adoption would significantly strengthen this criterion.

For OC4, the panel accepted your role as the first author of peer-reviewed publications but noted that the research had relatively limited external adoption at the time of assessment. Strengthening evidence of research impact through additional citations, independent implementation of your work, wider GitHub engagement, research collaborations, or evidence that other researchers or organisations have adopted or built upon your work may strengthen this criterion.

Regarding an endorsement review, based on the feedback, it doesn’t appear that the panel misunderstood your evidence; they assessed it but found it insufficient in scale. Unless you believe there has been a clear caseworking error or they overlooked evidence that would materially change the outcome, strengthening your profile and reapplying may be a more effective approach.

The fact that some evidence wasn’t specifically mentioned isn’t unusual. Tech Nation doesn’t comment on every document submitted, so the absence of a comment doesn’t necessarily mean it wasn’t reviewed. Overall, your feedback provides a fairly clear roadmap. I’d suggest you focus on increasing independent recognition, product traction, and research impact before reapplying.

2 Likes
13

The researcher who emailed to reproduce your code is the exact independent adoption OC4 needs, but it sounds like it went in as supporting narrative rather than a labelled artefact. In a reapplication, give that request its own evidence piece with the email chain and whatever the researcher built afterwards. One documented case of external uptake shifts a paper from too recent to being read.

OC1’s fix is trajectory. Week-on-week user and revenue graphs alongside the current figures give the assessor a growth curve, and even a modest one reads differently from a static number at the same absolute value.

2 Likes
14

@Noddy Thank you so much for taking the time to review my case and for such detailed advice. Your explanation has given me a much clearer direction for my reapplication.

Based on your experience, if I spend the next 6 months strengthening third-party recognition, product traction, and research impact, do you think it’s better to keep the same criteria (OC1 & OC4) with stronger evidence, or would you recommend changing one of the optional criteria?

15

@Akash_Joshi Thanks, I understand well now.

17

Keep OC1 and OC4. The panel accepted the product as genuine and the papers as first-author work, so the criteria fit isn’t what failed. The verdict was that both sat at too early a stage. Swapping criteria doesn’t fix that. New criteria means starting fresh, and the same sufficient-scale bar still applies.

The evidence you can build in six months maps directly onto what you already have. A documented paid NHS Trust pilot strengthens OC1 and can double as MC recognition. Independent citations plus external contributors adopting your GitHub implementation strengthen OC4.

Only consider swapping if a strong OC2 piece emerges naturally, such as a formal policy assessor role tied to your NHS engagement. Manufacturing OC2 or OC3 evidence in six months to escape a weak OC1 or OC4 will read as timing-driven and the assessor will discount it.

1 Like
18

@Shahzain To be honest, yes, you can do this, but don’t rely entirely on your previous application. The strategic approach is to learn from the mistakes and present evidence that properly aligns with the Tech Nation guidance at the time of application. This could be improved versions of your earlier evidence or a completely new set. What matters most is how well everything aligns with the current criteria. From what we’ve seen here, and from my experience with applicants, Tech Nation does not refer back to a previous application when assessing a new one.

All the best.

2 Likes
19

On the strengthen versus replace question: strengthen the existing set rather than swapping in new pieces. The panel accepted the product as genuine and the papers as first-author work. That means the evidence itself passed the authenticity bar. What failed was scale.

Replacing evidence starts you from zero on authenticity for the new pieces. Layering additional external validation onto what’s already accepted, such as an NHS pilot contract on top of Product X, or independent citations onto the existing papers, keeps the credibility banked and adds the missing scale on top.

2 Likes
20

If your plan over the next six months is to strengthen third-party recognition, product traction, and research impact, then continuing with OC1 (Innovation) and OC4 (Academic Contributions) could be a sensible approach, provided the additional evidence directly strengthens those criteria.

1 Like
21

@hsong427 on your questions

You see there are couple of reasons the OC4, I believe was rejected.

  1. For OC4 — did you include citation counts or Google Scholar data for the three papers as part of your evidence, or was “limited reach” more of an inference the panel made without you submitting citation metrics? If you did include citations, roughly how many did each paper have, and were they mostly independent researchers?

  1. “The evidence did not, however, demonstrate the calibre of research contribution required”
    The primary evidence required here is how an applicant contributed to the sector through research. This can be the topics’ relevance, if it sustained and what have we.

  2. “the publications are very recent”
    Tech Nation believe the publications are recent and would not have contributed to the sector, and also if all the papers are recent this can connote it was done for the purpose of the application.

  3. “and the evidence of their reach and adoption was minimal”
    Reach, this is where citation, readership, views and sownloads comes in

You see, citation you mentioned is not even a major reason for the rejection. Citation only validate that what you did is valuable and other experts used, referenced and adopted what you did. Reach like views, downloads are also major metrics to show impact.

  1. For OC1 — did you show growth trend (e.g. week-over-week user/revenue numbers) or mainly a point-in-time snapshot? Wondering if trajectory matters as much as absolute numbers.

For OC1, I believe, they are saying whilst the product is genuine, other complementary evidence did not validate that it’s innovative.

1 Like